BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 26926646)

  • 1. Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition.
    Lahiri SD; Alm RA
    Antimicrob Agents Chemother; 2016 May; 60(5):3183-6. PubMed ID: 26926646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
    Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
    J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance.
    Lahiri SD; Johnstone MR; Ross PL; McLaughlin RE; Olivier NB; Alm RA
    Antimicrob Agents Chemother; 2014 Oct; 58(10):5704-13. PubMed ID: 25022578
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
    Chalhoub H; Sáenz Y; Nichols WW; Tulkens PM; Van Bambeke F
    Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.
    Bradford PA; Huband MD; Stone GG
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.
    Lahiri SD; Bradford PA; Nichols WW; Alm RA
    J Antimicrob Chemother; 2016 Oct; 71(10):2848-55. PubMed ID: 27402011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
    Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
    Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates.
    Levasseur P; Girard AM; Claudon M; Goossens H; Black MT; Coleman K; Miossec C
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1606-8. PubMed ID: 22214778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases.
    Levasseur P; Girard AM; Miossec C; Pace J; Coleman K
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1931-4. PubMed ID: 25583732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
    Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays.
    Berkhout J; Melchers MJ; van Mil AC; Nichols WW; Mouton JW
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1138-44. PubMed ID: 25487794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.
    Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF
    J Antimicrob Chemother; 2018 Oct; 73(10):2777-2781. PubMed ID: 30010951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.
    Hackel M; Kazmierczak KM; Hoban DJ; Biedenbach DJ; Bouchillon SK; de Jonge BL; Stone GG
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4677-83. PubMed ID: 27216054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).
    de Jonge BL; Karlowsky JA; Kazmierczak KM; Biedenbach DJ; Sahm DF; Nichols WW
    Antimicrob Agents Chemother; 2016 May; 60(5):3163-9. PubMed ID: 26926648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients.
    Chalhoub H; Tunney M; Elborn JS; Vergison A; Denis O; Plésiat P; Kahl BC; Van Bambeke F; Tulkens PM
    J Antimicrob Chemother; 2015 May; 70(5):1596-8. PubMed ID: 25587996
    [No Abstract]   [Full Text] [Related]  

  • 18. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.
    Humphries RM; Yang S; Hemarajata P; Ward KW; Hindler JA; Miller SA; Gregson A
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6605-7. PubMed ID: 26195508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15.
    Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF
    J Antimicrob Chemother; 2018 Oct; 73(10):2782-2788. PubMed ID: 30010894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
    Mushtaq S; Vickers A; Woodford N; Livermore DM
    J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.